Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) EBITDA Margin (2016 - 2025)

BioCorRx (BICX) has disclosed EBITDA Margin for 15 consecutive years, with 1331.36% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin changed N/A to 1331.36% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 701.74% through Dec 2025, up 6571103.0% year-over-year, with the annual reading at 604.17% for FY2025, 6580860.0% up from the prior year.
  • EBITDA Margin hit 1331.36% in Q4 2025 for BioCorRx, down from 306.05% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 306.05% in Q3 2025 to a low of 33694.26% in Q2 2024.
  • Historically, EBITDA Margin has averaged 8374.27% across 5 years, with a median of 5119.6% in 2023.
  • Biggest five-year swings in EBITDA Margin: crashed -2890445bps in 2024 and later surged 3290331bps in 2025.
  • Year by year, EBITDA Margin stood at 9742.67% in 2021, then soared by 85bps to 1422.86% in 2022, then crashed by -203bps to 4310.34% in 2023, then crashed by -682bps to 33694.26% in 2024, then soared by 96bps to 1331.36% in 2025.
  • Business Quant data shows EBITDA Margin for BICX at 1331.36% in Q4 2025, 306.05% in Q3 2025, and 790.96% in Q2 2025.